The Swedish molecular diagnostics firm will use the proceeds, in part, to fund the planned launch of its Immray PanCan-d assay for detecting pancreatic cancer.
The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.
The company — which was cofounded by David Liu, Feng Zhang, and Keith Joung — has licensed base editing technology from Harvard and the Broad Institute.
The startup plans to harness single-cell genomics and computational analysis to discover therapies for autoimmune disease and cancer.
The firm said that its technology enables the detection of rare DNA variants with high accuracy to enable liquid biopsy diagnosis and treatments for multiple diseases.
The firm also offers an NIPT, codeveloped with Yale, that its CEO said is differentiated by its rapid time-to-result.
The company, which recently entered the next-generation sequencing sample prep market, said it has raised $259 million since it was founded in 2013.
It will use the funds to help expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection.
The company will use the funding to build a manufacturing facility, expand commercialization efforts, and develop new products.
Genetic Technologies and Blockchain Global may partner to develop medical and biotechnology applications that combine their respective technologies.
US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.
In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.